CLINICAL RESEARCH: HEART TRANSPLANTATION
Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices
Matteo Vatta, PhD* ,
Sonny J. Stetson, BSc  ||¶,
Shinawe Jimenez, MD*,
Mark L. Entman, MD¶#,
George P. Noon, MD¶#,
Neil E. Bowles, PhD*,
Jeffrey A. Towbin, MD* and
Guillermo Torre-Amione, MD, PhD||¶,*
* Department of Pediatrics (Cardiology), Baylor College of Medicine, Houston, Texas, USA
Department of Reproductive and Developmental Sciences, University of Trieste, Trieste, Italy
Section of Cardiology, Houston, Texas, USA
Cardiovascular Science, Houston, Texas, USA
|| Molecular and Human Genetics), Houston, Texas, USA
¶ The Winters Center for Heart Failure Research, Houston, Texas, USA
# The Gene and Judy Campbell Laboratory for Cardiac Transplant Research, and the Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, Texas, USA
Manuscript received April 16, 2003;
revised manuscript received August 1, 2003,
accepted September 22, 2003.
* Reprint requests and correspondence: Dr. Guillermo Torre-Amione, Methodist DeBakey Heart Center and Baylor College of Medicine, 6550 Fannin, Ste. 1901, Houston, Texas 77030, USA.
gtorre{at}bcm.tmc.edu
OBJECTIVES: We investigated the integrity of dystrophin in left ventricle (LV) and right ventricle (RV) of patients with end-stage heart failure due to ischemic cardiomyopathy (IHD) or dilated cardiomyopathy (DCM), and compared the efficacy of pulsatile or continuous flow assist devices on dystrophin reverse remodeling.
BACKGROUND: Recently we demonstrated that the amino (N)-terminus of dystrophin is preferentially disrupted in failing LV myocardium irrespective the underlying etiology, and that this defect is reversed by mechanical unloading using left ventricular assist device (LVAD) therapy.
METHODS: Myocardial samples were obtained from seven normal controls, seven failing hearts (either DCM or IHD), and 14 failing-heart patients who underwent placement of either pulsatile (7 patients) or continuous flow (7 patients) LVADs for progressive refractory HF. The expression and integrity of dystrophin in these samples were determined by immunohistochemistry using antibodies against the N-terminal and carboxyl (C)-terminal domains.
RESULTS: Immunohistochemical staining identified disruption of the N-terminal dystrophin in both LVs and RVs of all seven failing-heart patients, whereas the C-terminus was normal. Furthermore, this disruption was reversed in 12 of the 14 patients after LVAD therapy using either pulsatile or continuous devices; the degree of the reverse remodeling was similar in both ventricles, although greater recovery was noted in patients treated with pulsatile flow devices.
CONCLUSIONS: Integrity of the N-terminus of dystrophin is a useful indicator of both LV and RV function. In addition to improving LV hemodynamics, LVAD therapy results in amelioration of the myocardial structure of the right cardiac chamber.
|
Abbreviations and Acronyms
| | BMD | = Becker muscular dystrophy | | DAPC | = dystrophin-associated protein complex | | DMD | = Duchenné muscular dystrophy | | HF | = heart failure | | IHD | = ischemic cardiomyopathy | | LV | = left ventricle/ventricular | | LVAD | = left ventricular assist device | | N | = amino | | RV | = right ventricle/ventricular | | XLCM | = X-linked form of dilated cardiomyopathy |
|
This article has been cited by other articles:
|
|
|
|
 
J. A. Towbin and M. Vatta
Myocardial Infarction, Viral Infection, and the Cytoskeleton: Final Common Pathways of a Common Disease?
J. Am. Coll. Cardiol.,
December 4, 2007;
50(23):
2215 - 2217.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ghio, S. Perlini, G. Palladini, N. A. Marsan, G. Faggiano, M. Vezzoli, C. Klersy, C. Campana, G. Merlini, and L. Tavazzi
Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis
Eur J Heart Fail,
August 1, 2007;
9(8):
808 - 813.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hikoso, Y. Ikeda, O. Yamaguchi, T. Takeda, Y. Higuchi, S. Hirotani, K. Kashiwase, M. Yamada, M. Asahi, Y. Matsumura, et al.
Progression of Heart Failure Was Suppressed by Inhibition of Apoptosis Signal-Regulating Kinase 1 Via Transcoronary Gene Transfer
J. Am. Coll. Cardiol.,
July 31, 2007;
50(5):
453 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.W. Ashford Jr, W. Liu, S.J. Lin, P. Abraszewski, S.D. Caruthers, A.M. Connolly, X. Yu, and S.A. Wickline
Occult Cardiac Contractile Dysfunction in Dystrophin-Deficient Children Revealed by Cardiac Magnetic Resonance Strain Imaging
Circulation,
October 18, 2005;
112(16):
2462 - 2467.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Birks, J. L. Hall, P. J.R. Barton, S. Grindle, N. Latif, J. P. Hardy, J. E. Rider, N. R. Banner, A. Khaghani, L. W. Miller, et al.
Gene Profiling Changes in Cytoskeletal Proteins During Clinical Recovery After Left Ventricular-Assist Device Support
Circulation,
August 30, 2005;
112(9_suppl):
I-57 - I-64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Sanders
Did they lower stress in the trial?: Or was it just wasted energy?
J. Am. Coll. Cardiol.,
March 15, 2005;
45(6):
858 - 859.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, B. H. Greenberg, J. D. Knoke, K. U. Knowlton, W. Y.W. Lew, J. Narula, D. Sahn, et al.
Highlights of the year in JACC 2004
J. Am. Coll. Cardiol.,
January 4, 2005;
45(1):
137 - 153.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C J McMahon, M Vatta, C D Fraser Jr, J A Towbin, and A C Chang
Altered dystrophin expression in the right atrium of a patient after Fontan procedure with atrial flutter
Heart,
December 1, 2004;
90(12):
e65 - e65.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Pieske
Reverse remodeling in heart failure - fact or fiction?
Eur. Heart J. Suppl.,
August 1, 2004;
6(suppl_D):
D66 - D78.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
